LOGIN  |  REGISTER
Chimerix
C4 Therapeutics

Becton Dickinson Announces Dates for Third Quarter and Fourth Quarter Fiscal 2024 Earnings Webcasts

June 20, 2024 | Last Trade: US$227.68 3.85 1.72

FRANKLIN LAKES, N.J., June 20, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to discuss quarterly financial results on the following dates:

  • Third Quarter Fiscal 2024 —Thursday, August 1, 2024 at 8:00 a.m. (ET)
  • Fourth Quarter Fiscal 2024 — Thursday, November 7, 2024 at 8:00 a.m. (ET)

BD will issue a detailed announcement prior to each quarter's webcast, confirming the date and time of the earnings news release and webcast for that quarter.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

Contacts:

 

Media:

Investors:

Troy Kirkpatrick

Adam Reiffe

VP, Public Relations

Sr. Director, Investor Relations

858.617.2361

201.847.6927

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB